PTGX

Healthcare

Protagonist Therapeutics, Inc.

Revenue TTMXBRL

—

Net IncomeXBRL

—

Gross MarginXBRL

—

EPS (Diluted)XBRL

—

No analysis generated yet. Run the pipeline for this company.

AI-extracted key facts from press releases and SEC filings. Significance 1–10.

EarningsBullishPer-CompanyMay 5, 2026

Protagonist Therapeutics receives $50M milestone payment following FDA approval of icotrokinra

▸ICOTYDE (icotrokinra) FDA approved for moderate-to-severe plaque psoriasis in March
▸Received $50 million milestone payment from partnership
▸Eligible for up to $580 million in additional future milestone payments
▸Entitled to tiered royalties ranging from 6% to 10% on net sales
▸Q1 2026 financial results and corporate update provided

RegulatoryBullishPer-CompanyMar 20, 2026

FDA approves JNJ's Icotyde for plaque psoriasis, benefiting partner Protagonist Therapeutics

▸FDA approved Icotyde (icotrokinra) for moderate-to-severe plaque psoriasis
▸Icotyde indicated for adults and pediatric patients aged 12 and older
▸PTGX shares rose 4.7% following the regulatory approval announcement
▸Icotyde currently under evaluation for psoriatic arthritis, ulcerative colitis, and Crohn's disease
▸Upcoming quarterly revenue expected at $5M, down 82.3% year-over-year

ProductBullishPer-CompanyMar 18, 2026

FDA approves ICOTYDE for plaque psoriasis, triggering $50M milestone for Protagonist Therapeutics